<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>CatsWannaBeCats.Com | Drake Nieves | Activity</title>
	<link>https://www.catswannabecats.com/members/mothermom8/activity/</link>
	<atom:link href="https://www.catswannabecats.com/members/mothermom8/activity/feed/" rel="self" type="application/rss+xml" />
	<description>Activity feed for Drake Nieves.</description>
	<lastBuildDate>Tue, 30 Jun 2026 07:59:13 -0400</lastBuildDate>
	<generator>https://buddypress.org/?v=7.2.0</generator>
	<language>en-CA</language>
	<ttl>30</ttl>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>2</sy:updateFrequency>
	
						<item>
				<guid isPermaLink="false">c8862c4d2ccaca64cc44dbb1512f1a1d</guid>
				<title>Drake Nieves posted an update: 42 (95% CI, 0.26 to 0.62) and 0.83 (95% CI, 0.65 to 0.95), [&#133;]</title>
				<link>https://www.catswannabecats.com/activity/p/23512/</link>
				<pubDate>Sun, 08 Jun 2025 09:24:03 -0400</pubDate>

									<content:encoded><![CDATA[<p>42 (95% CI, 0.26 to 0.62) and 0.83 (95% CI, 0.65 to 0.95), respectively, and 0.43 (95% CI, 0.28 to 0.61) and 0.82 (95% CI, 0.68 to 0.93), respectively, with the cyclic regimen. <a href="https://www.selleckchem.com/products/mgd-28.html" rel="nofollow ugc">learn more</a> Serious adverse events occurred in 19% of patients receiving rituximab and in 14% receiving the cyclic regimen.</p>
<p> This pilot trial found no signal of more&hellip;<span class="activity-read-more" id="activity-read-more-23512"><a href="https://www.catswannabecats.com/activity/p/23512/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">88aa0ef635cd87f9e21b6227a601dbb0</guid>
				<title>Drake Nieves posted an update: Furthermore, there was a 5-fold increase in PVSA processing [&#133;]</title>
				<link>https://www.catswannabecats.com/activity/p/12626/</link>
				<pubDate>Sun, 01 Jun 2025 11:28:13 -0400</pubDate>

									<content:encoded><![CDATA[<p>Furthermore, there was a 5-fold increase in PVSA processing costs. The first post-vasectomy semen sample demonstrated azoospermia or RNMS in 97.5% of patients.</p>
<p> British guidelines are more resource intensive, result in prolonged follow-up with increasing rates of special clearance. The European Association of Urology permits clearance, not&hellip;<span class="activity-read-more" id="activity-read-more-12626"><a href="https://www.catswannabecats.com/activity/p/12626/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">e7112429efe0d80ed7eee380ce74935d</guid>
				<title>Drake Nieves posted an update: The objective of this study was to evaluate the outcome of a [&#133;]</title>
				<link>https://www.catswannabecats.com/activity/p/4551/</link>
				<pubDate>Sat, 31 May 2025 13:20:22 -0400</pubDate>

									<content:encoded><![CDATA[<p>The objective of this study was to evaluate the outcome of a special interdisciplinary hand therapy program depending on the time interval between trauma and rehabilitation.</p>
<p> With use of self-assessed scores (Disability of the Arm, Shoulder and Hand Score , European Quality of Life 5 Dimensions ) and objective functional parameters (TAM =&hellip;<span class="activity-read-more" id="activity-read-more-4551"><a href="https://www.catswannabecats.com/activity/p/4551/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">e81db36f38623e762e77bb3777d184ef</guid>
				<title>Drake Nieves became a registered member</title>
				<link>https://www.catswannabecats.com/activity/p/4405/</link>
				<pubDate>Sat, 31 May 2025 12:46:48 -0400</pubDate>

				
									<slash:comments>0</slash:comments>
				
							</item>
		
	</channel>
</rss>